Abnova - AGM Information 2024 | FinancialReports.eu

(This translated document is prepared in accordance with the Chinese version and is for reference only. In theevent of any inconsistency between the English version and the Chinese version, the Chinese version shall prevail.)

Abnova `（` Taiwan `）` Corporation Meeting Minutes of General Shareholders’ Meeting 2024

Type of Meeting: Physical shareholders’ meeting

Time: 9 a.m. on Wednesday, May 22, 2024

Place: 1F., No. 207, Sec. 2, Tiding Blvd., Neihu Dist., Taipei City, Taiwan (R.O.C.)

(XUE XUE Foundation Building)

Total outstanding shares of Abnova （ Taiwan ） Corporation ： 60,553,594 shares

Total shares represented by shareholders present (including the shares with e-voting rights 1,504,948 shares) ： 35,562,762 shares

Percentage of shares held by shareholders present ： 58.72%

Direct Present: Wilber Huang (Chairperson), Chiu Chi Ching (Representative of Harmony Investment

Co., Ltd.), Jih Pei Ju (Representative of Pan Pacific Investment Corp.), Cha Anna (Convener of Audit Committee), Ye Shao De, Su Jin Jun

Attendees: Chang Ya Ping (Accounting Officer), Kuo Rou Lan (KPMG Certified Public Accountant)

Chairperson: Wilber Huang, the chairperson of Board of Directors

Secretary: Tung I Ling

1. Call the Meeting to Order:

The aggregate shareholding of the shareholders present constituted a quorum. The Chairman called the meeting to order.

2. Chairperson Remarks: (omitted)

3. Reported Matters

(1) 2023 Business Report (please refer to Appendix 1)
(2) Audit Committee’s Review Report on the 2023 Financial Statements (please refer to

Appendix 2)

(3) Remuneration Distribution Report for Employees and Directors of 2023 (please refer to MEETING HANDBOOK Page 2)
(4) 2023 Remuneration report of directors (please refer to MEETING HANDBOOK Page 2~5)
(5) 2023 Profit Distribution Report (please refer to Appendix 4)
(6) Amendment Report to Rules of Procedure for Board of Directors (please refer to Appendix 5)
1 -

4. Matters for Ratification

No. 1 (Proposed by the Board)

Proposal: Adoption of 2023 Business Report and Financial Statements Explanation:

2023 Financial statements (including individual and consolidated statements) have been audited by KPMG Certified Public Accountants, Chiang Hsiao Ling and Guo Ju Lan, and issued an audit report, which has been reviewed by the Audit Committee.
2023 Business Report, 2023 Inspection Report of Audit Committee, 2023 Annual Financial Statements and CPA's Audit Report, please refer to Appendix 1-3.
Please adopt.

Resolution:

The proposal was approved by the votes of shareholders present. The voting results as follows.

Shares represented at the time of voting: 35,562,762

3. Please adopt. olution: The proposal was approved by the votes of shareholders present. follows. Shares represented at the time of voting: 35,562,762	The voting results as
Voting Results	% of the total represented sharepresent
Votes in favor: 34,494,949 votes (including869,079 votes casted electronically)	96.99%
Votes against: 40,078 votes (including40,078 votes casted electronically)	0.11%
Votes invalid: 0 vote	0.00%
Votes abstained: 1,027,735 votes (including595,791 votes casted electronically)	2.88%

※The percentage of shareholders' voting rights is unconditionally rounded to the second decimal place, which may result

in a fractional difference, resulting in the total number of percentages not equal to 100%.

No.2

(Proposed by the Board)

Proposal: Adoption of 2023 Profit Distribution

Explanation:

The accumulated unappropriated retained earnings are NTD 64,923,293, added the net profit after tax in 2023 is NTD 43,677,854. Lessed NTD 618,052 earnings due to remeasurements of the net defined benefit plan and set aside NTD 4,305,980 legal reserve and NTD 291,781 special reserve, the distributable net profit is NTD 103,385,334. The proposed dividend to shareholders is NTD 43,598,588. The distribution of shareholder dividends is planned to be distributed preferentially from the 2023 profit. To learn more about the 2023 Profit distribution statement, please refer to Appendix 4.
2 -
This cash dividend is calculated based on the shareholding ratio recorded in the shareholder register on the ex-dividend base date (rounded down to the nearest dollar). The total amount of odd lots (less than one full share) will be purchased by people designated by the chairperson as authorized by the board of directors.
After the proposal is approved by the shareholders' regular meeting, the board of directors shall set the ex-dividend base date and other relevant matters.
If, before the distribution record date, the proposed profit distribution is affected by a buyback of shares or issuance of new shares for transferring treasury shares, cancellation or capital reduction, etc. causing changes in the number of outstanding shares, it is proposed that the Board of Directors be authorized to adjust the cash to be distributed to each share.
Please adopt.

Resolution:

The proposal was approved by the votes of shareholders present. The voting results as follows.

Shares represented at the time of voting: 35,562,762

olution: The proposal was approved by the votes of shareholders present. follows. Shares represented at the time of voting: 35,562,762	The voting results as
Voting Results*	% of the total represented sharepresent
Votes in favor: 34,503,181 votes (including877,311 votes casted electronically)	97.02%
Votes against: 36,357 votes (including36,357 votes casted electronically)	0.10%
Votes invalid: 0 vote	0.00%
Votes abstained: 1,023,224 votes (including591,280 votes casted electronically)	2.87%

※The percentage of shareholders' voting rights is unconditionally rounded to the second decimal place, which may result

in a fractional difference, resulting in the total number of percentages not equal to 100%.

5. Questions and Motions: None

There was no question raised by shareholders at the shareholders' meeting regarding the Reported Matters, Matters for Ratification and Questions and Motions.

6. Adjournment

On Monday, May 22, 2024, the Chair declared the meeting adjourned at 9:18 a.m.

 The meeting minutes only specify the gist of the meeting, and the contents and procedures of the meeting are subject to the audio and video of the meeting.

Appendix 1 Abnova `（` Taiwan `）` Corporation 2023 Business Report

Appreciate shareholders’ support of Abnova. The following is Abnova's 2023 achievement sharing and 2024 outlook report:

I. 2023 Operating Results: (Consolidated Financial Statements)

Implementation overview and business plan implementation results: The operating revenue in 2023 was NTD 382,052,000, which is 7.2% lower than the 2022 operating income of NTD 411,756,000. The net income after tax in 2023 was NTD 43,678,000, which is a decrease of 41.64% compared with the net profit after tax of NTD 74,843,000 in 2022. 2023 EPS is NTD 0.72.
Analysis of financial balance and profitability: Please refer to the attached financial statements for the financial overview of 2023.
Research Development Overview: The expenses invested in research and development in 2023 was NTD 38,396,000, which is 21.22% lower than the 2022 expenses of NTD 48,740,000. The R&D mainly involves the products relevant to the applications of recombinant antibodies, nanobodies, miRNA, and mRNA cancer vaccine therapy platforms.

II. 2024 Business Plan:

1. Business Marketing:

Abnova engages in the sales of biological reagents for scientific research primarily through global-scale distributors and regional distributors in various countries. Abnova launched its new website in 2023, offering a more convenient and seamless online ordering experience for direct-sale customers and a user-friendly member center. The website incorporates interface concepts centering on mobile devices, presenting a fresh and improved visual appearance with enhanced user privacy protection. This aims to meet consumer demands and enhance the willingness of end customers to place orders directly on the website. In 2024, Abnova will continue to optimize its website to improve user satisfaction.

2. Product Development:

(1) miRNA Probe Customization and Catalog Products:

In Q3 2023, Abnova launched a new miRNA probe customization service and catalog products to meet the growing demand for miRNA research tools in both academic and industrial sectors. miRNA probes play a crucial role in studying miRNA expression, gene regulation, functional analysis, biomarker relevance, and drug development in biological samples. Abnova offers customization services and highly sensitive miRNA probes to meet various research needs and plans to continue expanding its miRNA catalog product line in 2024 to better cater to the evolving market demands, providing the most advanced miRNA research tools with more choices to support customers in the development of miRNA-related research fields.

miRNA Probe Customization Service:
https://www.abnova.com/en global/services/mirna_probes
miRNA Probe Catalog:

https://www.abnova.com/en-global/product/filter?category=ARAN00000000

(2) miRNA (circRNA) Sponge

miRNA (circRNA) Sponge is an artificial non-coding circular RNA. By integrating multiple miRNA targeting fragments on the miRNA sponge, the diversity of miRNA sponge adsorption can be increased. Compared to linear miRNA sponges, circular miRNA sponges lack 5' and 3' ends, exhibit low immunogenicity without the need for nucleoside modification, and resist degradation by nucleases, thereby enhancing adsorption stability and efficiency. miRNA sponges also overcome the toxicity concerns of traditional anti-miRNA oligonucleotides (AMOs) and dosage limitations associated with plasmid-based miRNA sponges. In 2023, Abnova successfully launched a new miRNA sponge product line and plans to expand its catalog product line in 2024 to provide stable and efficient miRNA sponge products, supporting both in vivo and in vitro miRNA research fields.

 miRNA Sponge Technology:

https://www.abnova.com/en global/support/technologies/circrna_sponge

(3) Recombinant Antibodies:

Recombinant antibodies are antibodies prepared through DNA sequence recombination technology, distinguished from the traditional preparation of mouse monoclonal antibodies, which involves immunizing mice, isolating B cells from their spleen or lymph nodes, and then fusing them with myeloma cell lines to select hybridoma cell lines that secrete antibodies. In contrast, recombinant antibodies are prepared through in vitro DNA sequence recombination technology, where the genes encoding the antibody's light and heavy chains are inserted into expression vectors and transfected into host cells for antibody expression. Recombinant antibodies offer several advantages, including high specificity and sensitivity, as well as superior batch-to-batch consistency. Furthermore, recombinant antibodies allow for antibody quantification using mammalian cell lines, eliminating the need for antibody quantification preparations relying on mouse ascites production, thus adhering to the 3R principle of animal experimentation.

Abnova provides a variety of high-quality recombinant antibody options rigorously tested for their specificity to meet diverse customer demands for antibodies. In 2024, Abnova will continue to improve the qualitative results of its recombinant antibody catalog products to meet customer needs with more comprehensive qualitative data.

Recombinant Antibody Catalog Products:
https://www.abnova.com/en global/product/specializedproductsearch/recomab

(4) Nanobodies:

Compared to traditional antibodies, nanobodies demonstrate several significant advantages. Nanobody molecules have a molecular weight of only one-tenth that of traditional antibodies, rendering better solubility and easier penetration of cellular tissues. Nanobodies possess higher antigen affinity, enabling them to bind more firmly and stably to antigens. Meanwhile, the low immunogenicity of nanobodies reduces the risk of immune reactions. The mass production of nanobodies can be made possible rapidly and stably through mammalian cell lines. These advantages make nanobodies promising in a wide range of applications in medical research, disease diagnosis, and treatment, particularly in the pharmaceutical industry, where they have the potential to overcome the limitations of traditional antibodies. Abnova's nanobody products not only offer customized services but also launched a nanobody catalog product at the end of 2023. In 2024, Abnova will continue to expand its catalog of targeted human gene-related nanobody products, providing refined catalog products to meet customer demands and offering more convenient choices for customers.

5 -
Nanobodies Customization Service:
https://www.abnova.com/en global/services/nanoab_service_1
Nanobodies Catalog Products: -
https://www.abnova.com/en global/product/specializedproductsearch/camelid

(5) CellTX[TM] Regeant for Cytotherapy:

The cytotherapy market continues to thrive, especially in the field of cancer treatment. Abnova has integrated the CellTX[TM] cytotherapy product line from the end of 2023 to 2024, meanwhile launching three types of cytotherapy reagents:

(1) GMP-Grade Protein for Cell Culture in Cytotherapy:
Cytotherapy procedures require the isolation and expansion of specific cells in vitro, and various cytokines are needed during the culture process to expand specific cells. Abnova is committed to meeting the high-quality demand for GMP-grade proteins for cell culture in the cytotherapy market. In Q1 2024, Abnova launched GMP-grade proteins specifically designed for cytotherapy cell culture to meet the growing demands of the expanding cytotherapy market. Abnova also provides cytotherapy culture proteins for scientific research purposes to meet different user needs.
(2) The Humanized Monoclonal Antibodies Relevant to Cytotherapy: Humanized monoclonal antibodies retain the complementarity-determining region sequences of mouse monoclonal antibodies, maintaining the affinity and specificity of the original mouse monoclonal antibodies. Other sequences are modified through humanization engineering to replace them with human antibody sequences, reducing immunogenicity and improving test safety. These antibodies are crucial in cancer research and the development of new drugs for autoimmune diseases. Leveraging years of antibody production experience, Abnova provides premium humanized monoclonal antibody catalog products for cytotherapy research through antibody humanization engineering, offering customers convenient research tools to meet the rapid development needs in the field of cytotherapy.
(3) Human and Mice CD3/CD28 ActiveBeads[TM] :
The cytotherapy process involves isolating specific cells from the blood for activation and expansion in vitro. Therefore, suitable cell activation reagents are essential for developing cytotherapy drugs. In 2023, Abnova began developing T-cell activation reagents. Through various processes including the development of CD3, and CD28 monoclonal antibodies to antibody humanization, and coupling of humanized antibodies with beads, Abnova successfully developed Human CD3/CD28 ActiveBeads[TM] . Furthermore, Abnova simultaneously launched Mouse CD3/CD28 ActiveBeads[TM] in response to the demand for mouse model testing in the development stages of cytotherapy drugs, meeting the needs of users in various stages of development.
CellTX[TM] Cytotherapy Reagent Catalog Products: https://www.abnova.com/en-global/product?category=BA0000000000

(6) mRNA Cancer Vaccine Treatment Platform Development:

The Abnova mRNA cancer vaccine therapy platform integrates antigen targets, expression vector design, and non-viral vector technology with LNP delivery, replacing the slow virus system with high manufacturing costs and limited scalability under the existing business models. It is expected that in 2024, optimization of the mRNA cancer vaccine for triple-negative breast cancer (TNBC) will be completed through testing in mouse models,

followed by GLP preclinical animal studies and pharmacokinetic tests. Based on the data, continuous progress will be made to refine preclinical trial data.

III. The effect of external competition, the legal environment, and the overall business environment

1. External Competition:

In recent years, the health of humankind and the global economy has been impacted by the outbreak of COVID-19 and various infectious diseases, leading to increasing attention to the biotechnology and medicine industry.

Various countries have introduced incentive policies, which will attract many competitors to join, but also promote the vigorous development of the biotechnology and medical industry, cultivating more outstanding talents, which is expected to contribute to the long-term development of the whole industry.

2. Legal Environment:

Abnova strictly controls product quality and has ISO9001 certification of Neihu Plant. In response to the needs of different products and countries, relevant laws and regulations of various countries shall be followed. Meeting the above specifications will increase the management and application costs, but at the same time, it can also guarantee product quality and improve customer recognition.

3. Overall Business Environment:

About 97% of Abnova's products are exported, and the main sales areas are America, Europe, Japan, etc. The transaction currency is mainly USD, followed by Euro. Since the recent fluctuations in the US dollar exchange rate have had an impact on the Company, the financial department closely observes the exchange rate trend and timely assesses whether to conduct hedging derivative financial commodity transactions to reduce the exchange rate risk.

In 2024, Abnova will adhere to the original intention of professionalism, focus, and quality, and continue to push itself for deeper technological innovation. Looking forward to the future, it may face variable operational opportunities and challenges. Abnova will continue to strengthen its competitive strength and accumulate more growth momentum to create better operating results.

Chairperson: Wilber Huang

General Manager: Jih Pei Ju

Accounting Officer: Chang Ya Ping

Appendix 2

Abnova `（` Taiwan `）` Corporation Inspection Report of Audit Committee

The Board of Directors prepared the Company's business report, financial statements, and profit distribution proposal for 2023. The financial statements have been audited by KPMG accounting firm and an audit report has been issued. The above business report, financial statements, and profit distribution proposal have been audited by the Audit Committee and there is no nonconformity, so the feedback is reported as above in accordance with the relevant provisions of the Securities and Exchange Act and the Company Act, please proceed to the certificate.

Abnova （ Taiwan ） Corporation Convener of Audit Committee: Cha Anna February 27, 2024

Appendix 3 Independent Auditors’ Report

To the Board of Directors of Abnova (Taiwan) Corporation:

Opinion

We have audited the consolidated financial statements of Abnova (Taiwan) Corporation and its subsidiaries (“the Group”), which comprise the consolidated balance sheets as of December 31, 2023 and 2022, the consolidated statements of comprehensive income, changes in equity, and cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of Abnova (Taiwan) Corporation and its subsidiaries as of December 31, 2023 and 2022, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and with the International Financial Reporting Standards (“IFRSs”), International Accounting Standards (“IASs”), Interpretations developed by the International Financial Reporting Interpretations Committee (“IFRIC”) or the former Standing Interpretations Committee (“SIC”) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for opinion

We conducted our audits in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and auditing standards. Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Consolidated Financial Statement section of our report. We are independent of the Group in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. The key audit matters we judge that shall be communicated in the audit report are as follows:

1. Inventory valuation

Please refer to Note 4(8) “Inventories”; Note 5(1) “Significant accounting assumptions and judgments, and major sources of estimation uncertainty”, and Note 6(5) “Inventories”.

Description of key audit matter:

The major business of the Group is the manufacturing and sales of antibodies, proteins, test reagents, and testing instruments. Inventories are measured at a lower cost and net realizable value. Due to the longer life cycle of the products, the management considers factors such as product circulation, exposure, preservation, and industry information to evaluate the net realizable value of inventories. As Abnova (Taiwan) Corporation and its subsidiaries have a large amount of inventories and a large number of items, and the net realizable value used in the above-mentioned evaluation involves subjective judgment, the evaluation of loss allowance for inventory valuation has been listed as the key audit matter of the year.

Our principal audit procedures included:

The key audit procedures for the above-mentioned key audit matter based on the understanding of the industrial characteristics of Abnova (Taiwan) Corporation and its subsidiaries include obtaining statistical information on the sales time and sales status of the products on the shelves in each year provided by the management in the subsequent years to evaluate the rationality of the policy used to recognize the inventory valuation loss; understanding the Group and its subsidiaries inventory management process, reviewing the annual inventory plan and participating in the annual inventory check to evaluate the effectiveness of the management’s inventory control; obtaining the inventory net realizable value calculation sheet, and spot checks the correctness of the calculation.

Other matter

Abnova (Taiwan) Corporation has prepared its parent-company-only financial statements as of and for the years ended December 31, 2023 and 2022, on which we have issued an unqualified opinion.

Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and with the IFRSs, IASs, IFRC, SIC endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group’s ability to continue as a going concern, disclosing, as applicable, matters related to going concerned and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations or has no realistic alternative but to do so.

Those charged with governance (including the Audit Committee) are responsible for overseeing the Group’s financial reporting process.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with auditing standards, we exercise professional judgment and professional skepticism throughout the audit. We also:

A. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
B. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
10 -

effectiveness of the Group’s internal control.

C. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
D. Conclude on the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Group’s to cease to continue as a going concern.
E. Evaluate the overall presentation, structure, and content of the consolidated financial reports, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
F. Obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on consolidated financial statements. We are responsible for the direction, supervision, and performance of the group audit. We remain solely responsible for our audit opinion.
We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

KPMG

Auditors：

Securities Competent ：Financial-Supervisory-SecuritiesAuthority Auditing-1080303300 Approved-certified No. Financial-Supervisory-SecuritiesAuditing-1070304941 February 27, 2024

11 -

Abnova Corporation and Subsidiaries

Consolidated Balance Sheets

December 31, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars)

December 31, 2023 Amount ％ $ 423,515 32 491 - 39,432 3 31,099 2 408,302 30 16,983 1 919,822 68 - - 251 - 257,863 19 7,649 1 69,640 5 95,274 7 5,244 - 435,921 32 $ 1,355,743 100	December 31, 2023 Amount ％ $ 423,515 32 491 - 39,432 3 31,099 2 408,302 30 16,983 1 919,822 68 - - 251 - 257,863 19 7,649 1 69,640 5 95,274 7 5,244 - 435,921 32 $ 1,355,743 100	December 31, 2022 Amount ％ 367,065 27 246 - 59,999 4 95,657 7 396,079 29 9,146 - 928,192 67 - - 550 - 256,546 19 10,733 1 68,815 5 98,278 7 11,715 1 446,637 33 1,374,829 100 Liabilities and equity Current liabilities: 2130 Contract liability-current (Note 6(15)) 2170 Accounts payable 2200 Other payables 2230 Current tax liabilities 2280 Current lease liabilities (Note 6(10)) 2300 Other current liabilities Total current liabilities Non-current liabilities: 2570 Deferred tax liabilities (Note 6(12)) 2580 Non-current lease liabilities (Note 6(10)) 2600 Other non-current liabilities (Note 6(6) and 7) Total non-current liabilities Total liabilities Equity attributable to owners of parent (Note 6(13))`：` Ordinary share 3110 Capital surplus 3200 Retained earnings: Legal reserve 3310 Unappropriated retained earnings 3320 Special reserve 3350 Other equity interest 3400 Total equity Total liabilities and equity	December 31, 2023 Amount % $ 2,349 - 14,935 2 34,384 3 39 - 5,105 - 5,790 - 62,602 5 3,783 - 2,601 - 438 - 6,822 - 69,424 5 605,536 45 474,527 35 98,565 7 11,907 1 107,983 8 (12,199) (1) 1,286,319 95 $ 1,355,743 100	December 31, 2023 Amount % $ 2,349 - 14,935 2 34,384 3 39 - 5,105 - 5,790 - 62,602 5 3,783 - 2,601 - 438 - 6,822 - 69,424 5 605,536 45 474,527 35 98,565 7 11,907 1 107,983 8 (12,199) (1) 1,286,319 95 $ 1,355,743 100	December 31, 2022 Amount % 2,622 - 14,995 1 41,387 3 2,057 - 7,199 1 4,559 - 72,819 5 5,804 - 3,686 - 526 - 10,016 - 82,835 5 605,536 44 474,527 35 85,642 7 - - 138,196 10 (11,907) (1) 1,291,994 95 1,374,829 100	December 31, 2022 Amount % 2,622 - 14,995 1 41,387 3 2,057 - 7,199 1 4,559 - 72,819 5 5,804 - 3,686 - 526 - 10,016 - 82,835 5 605,536 44 474,527 35 85,642 7 - - 138,196 10 (11,907) (1) 1,291,994 95 1,374,829 100
Amount $ 423,515 491 39,432 31,099 408,302 16,983 919,822 - 251 257,863 7,649 69,640 95,274 5,244 435,921 $ 1,355,743		Amount 367,065 246 59,999 95,657 396,079 9,146 928,192 - 550 256,546 10,733 68,815 98,278 11,715 446,637 1,374,829	Amount $ 2,349 14,935 34,384 39 5,105 5,790		Amount 2,622 14,995 41,387 2,057 7,199 4,559 72,819 5,804 3,686 526 10,016 82,835 605,536 474,527 85,642 - 138,196 (11,907) 1,291,994 1,374,829

	68		62,602	5		5
	- - 19 1 5 7 -		3,783 2,601 438	- - -		- - -
			6,822	-		-
			69,424	5		5
			605,536 474,527 98,565 11,907 107,983 (12,199)	45 35 7 1 8 (1)		44 35 7 - 10 (1)
	32
			1,286,319	95		95
	100		$ 1,355,743	100		100

(See accompanying notes to financial statements.) Manager: JIH PEI JU

Chairperson: WILBER HUANG

Accounting supervisor: CHANG YA PING

12 -

Abnova (Taiwan) Corporation and Subsidiaries Consolidated Statements of Comprehensive Income For the years ended December 31, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars)

2023	％ 100 (55)	2022
Amount $ 382,052 (208,137)		Amount 411,756 (210,327)	％
			100 (51)
173,915	45	201,429	49
(45,261) (46,117) (38,396) 3,053	(12) (12) (10) 1	(40,349) (47,216) (48,740) (698)	(10) (11) (12) -
(126,721)	(33)	(137,003)	(33)
47,194	12	64,426	16
10,528 152 (8,976) (142) (239)	3 - (2) - -	3,636 971 26,075 (152) -	1 - 6 - -
1,323	1	30,530	7
48,517 4,839	13 1	94,956 20,113	23 5
43,678	12	74,843	18
(618) - -	- - -	304 28,730 -	- 7 -
(618)	-	29,034	7
(292) -	- -	4,216 -	1 -
(292)	-	4,216	1
(910)	-	33,250	8
$ 42,768	12	108,093	26
$	0.72		1.24
$	0.72		1.23

(See accompanying notes to financial statements.) Chairperson: WILBER HUANG Manager: JIH PEI JU Accounting supervisor: CHANG YA PING

13 -

Abnova (Taiwan) Corporation and Subsidiaries Consolidated Statements of Changes in Equity For the years ended December 31, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars)

		Equity attributable to owners of parent	Equity attributable to owners of parent	Equity attributable to owners of parent	Other equity interest Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income Exchange differences on translation of foreign financial statements (11,178) 20,407 - - 4,216 28,730	Other equity interest Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income Exchange differences on translation of foreign financial statements (11,178) 20,407 - - 4,216 28,730	Total equity 1,211,756 74,843 33,250
Shares	Capital surplus 474,527 - -		Retained earnings	Unappropriated retained earnings 39,698 74,843 304
					Exchange differences on translation of foreign financial statements (11,178) - 4,216
Ordinary shares		Legal reserve 82,766 - -	Special reserve - - -
-	-	-	-	75,147	4,216	28,730	108,093
- - -	- - -	2,876 - -	- - -	(2,876) (27,855) 54,082	- - -	- - (54,082)	- (27,855) -
605,536 - -	474,527 - -	85,642 - -	- - -	138,196 43,678 (618)	(6,962) - (292)	(4,945) - -	1,291,994 43,678 (910)
-	-	-	-	43,060	(292)	-	42,768
- - -	- - -	12,923 - -	- 11,907 -	(12,923) (11,907) (48,443)	- - -	- - -	- - (48,443)
$ 605,536	474,527	98,565	11,907	107,983	(7,254)	(4,945)	1,286,319

(See accompanying notes to financial statements.) Manager: JIH PEI JU

Chairperson: WILBER HUANG

Accounting supervisor: CHANG YA PING

14 -

Abnova (Taiwan) Corporation and Subsidiaries Consolidated Statements of Cash Flows For the years ended December 31, 2023 and 2022 (Expressed in Thousands of New Taiwan Dollars)

Cash flows from operating activities: Profit before tax Adjustments: Adjustments to reconcile profit (loss) Depreciation expenses Amortization expenses Expected credit loss (reversal gains) Interest expense Interest income Share of associates and joint ventures losses accounted for using the equity method Loss (gain) from the disposal of property, plant, and equipment Total adjustments to reconcile profit (loss) Changes in operating assets and liabilities: Changes in operating assets: Notes receivable Accounts receivable Other receivables Inventories Other current assets Total changes in operating assets Changes in operating liabilities: Contract liabilities Accounts payable Other payables Other current liabilities Total changes in operating liabilities Total changes in operating assets and liabilities Total adjustments Cash inflow generated from operations Interest received Interest paid Income taxes paid Net cash flows from operating activities Cash flows used in investing activities: Acquisition of property, plant, and equipment Proceeds from disposal of property, plant and equipment Other receivables Acquisition of intangible assets Other financial assets Other non-current assets Other non-current liabilities Net cash flows (outflows) used in investing activities Cash flows from financing activities: Guaranteed deposits received Repayment of lease principles Cash dividends paid Proceeds from disposal of subsidiaries' cash Net cash flows from financing activities Effect of exchange rate changes on cash and cash equivalents Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period	2023 $ 48,517 21,491 10,820 (3,053) 142 (10,528) 239 3,453	2022 94,956 23,754 10,739 698 152 (3,636) - (7)
	22,564	31,700
	(245) 23,620 7,819 (14,548) (7,827)	194 (12,335) (439) 9,314 3,794
	8,819	528
	(273) (60) (7,033) 1,231	(16) 3,515 3,504 708
	(6,135)	7,711
	2,684	8,239
	25,248	39,939
	73,765 10,072 (142) (7,476)	134,895 3,189 (152) (5,259)
	76,219	132,673
	(19,566) 160 59,760 (9,320) 786 5,059 (88)	(1,390) 45 - (5,240) 172 (7,165) (97)
	36,791	(13,675)
	- (7,177) (48,443) -	(4,423) (8,897) (27,855) (20,225)
	(55,620)	(61,400)
	(940) 56,450 367,065	2,746 60,344 306,721
	$ 423,515	367,065

(See accompanying notes to financial statements.) Chairperson: WILBER HUANG Manager: JIH PEI JU - 15 -

Accounting supervisor: CHANG YA PING

Independent Auditors’ Report

To the Board of Directors of Abnova (Taiwan) Corporation:

Opinion

We have audited the financial statements of Abnova (Taiwan) Corporation (“the Company”), which comprise the balance sheets as of December 31, 2023, and 2022, the statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and its financial performance and its cash flows for the years that ended by the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for Opinion

We conducted our audits by the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and auditing standards. Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Parent Company Only Financial Statement section of our report. We are independent of the Company by the Norm of Professional Ethics for Certified Public Accountants of the Republic of China and we have fulfilled our other ethical responsibilities by these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. The key audit matters we judge that shall be communicated in the audit report are as follows:

1. Inventory valuation

Please refer to Note 4(7) “Inventories”; Note 5(1) “Significant accounting assumptions and judgments, and major sources of estimation uncertainty”, and Note 6(5) “Inventories”.

16 -

Description of key audit matter:

The major business of the Company is the manufacturing and sales of antibodies, proteins, test reagents, and testing instruments. Inventories are measured at the lower cost and net realizable value. Due to the longer life cycle of the products, the management considers factors such as product circulation, exposure, preservation, and industry information to evaluate the net realizable value of inventories. As the Company has a large amount of inventories and a large number of items, and the net realizable value used in the above-mentioned evaluation involves subjective judgment, the evaluation of loss allowance for inventory valuation has been listed as the key audit matter of the year.

Our principal audit procedures included:

The key audit procedures for the above-mentioned key audit matter based on the understanding of the industrial characteristics of the Company include obtaining statistical information on the sales time and sales status of the products on the shelves in each year provided by the management in the subsequent years to evaluate the rationality of the policy used to recognize the inventory valuation loss; understanding the Company’s inventory management process, reviewing the annual inventory plan and participating in the annual inventory check to evaluate the effectiveness of the management’s inventory control; obtaining the inventory net realizable value calculation sheet, and spot checks the correctness of the calculation.

Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements by the Regulations Governing the Preparation of Financial Reports by Securities Issuers and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concerned and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

Those charged with governance (including the Audit Committee) are responsible for overseeing the Company’s financial reporting process.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted by the auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken based on these financial statements.

As part of an audit by auditing standards, we exercise professional judgment and professional skepticism throughout the audit. We also:

A. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

17 -
B. Obtain an understanding of internal control relevant to the audit to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the Company’s internal control.
C. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
D. Conclude on the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company’s to cease to continue as a going concern.
E. Evaluate the overall presentation, structure and content of the financial reports, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
F. Obtain sufficient and appropriate audit evidence regarding the financial information of the investment in other entities accounted for using the equity method to express an opinion on these financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

KPMG

Auditors：

Securities Competent ：Financial-Supervisory-SecuritiesAuthority Auditing -1080303300 Approved-certified No. Financial-Supervisory-SecurititiesAuditing-1070304941 February 27, 2024

18 -

Abnova (Taiwan) Corporation

Balance Sheets

December 31, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars)

December 31, 2023 Amount ％ $ 360,329 27 491 - 39,358 3 3,223 - 1,602 - 408,302 30 16,661 1 829,966 61 - - 87,431 7 257,749 19 7,649 1 69,640 5 95,274 7 5,238 - 522,981 39 $ 1,352,947 100	December 31, 2023 Amount ％ $ 360,329 27 491 - 39,358 3 3,223 - 1,602 - 408,302 30 16,661 1 829,966 61 - - 87,431 7 257,749 19 7,649 1 69,640 5 95,274 7 5,238 - 522,981 39 $ 1,352,947 100	December 31, 2022 Amount ％ 362,971 27 246 - 59,999 5 2,452 - - - 396,079 29 8,841 - 830,588 61 - - 97,564 7 252,134 18 10,422 1 68,815 5 98,278 7 11,715 1 538,928 39 1,369,516 100 Liabilities and equity Current liabilities: 2130 Contract liability-current (Note 6(15)) 2170 Accounts payable 2200 Other payables 2230 Current tax liabilities 2280 Current lease liabilities (Note 6(10)) 2300 Other current liabilities Total current liabilities Non-current liabilities: 2570 Deferred tax liabilities (Note 6(12)) 2580 Non-current lease liabilities (Note 6(10)) 2600 Other non-current liabilities (Note 6(6) and Note 7) Total non-current liabilities Total liabilities Equity (Note 6(13)) 3110 Ordinary share 3200 Capital surplus Retained earnings: 3310 Legal reserve 3320 Special reserve 3350 Unappropriated retained earnings 3400 Other equity interest Total equity Total liabilities and equity	December 31,	2023 % - 2 3 - - - 5 - - - - 5 45 35 7 1 8 (1) 95 100	December 31, 2022 Amount % 2,622 - 14,995 1 36,541 3 2,015 - 6,778 - 4,555 - 67,506 4 5,804 - 3,686 - 526 - 10,016 - 77,522 4 605,536 45 474,527 35 85,642 7 - - 138,196 10 (11,907) (1) 1,291,994 96 1,369,516 100	December 31, 2022 Amount % 2,622 - 14,995 1 36,541 3 2,015 - 6,778 - 4,555 - 67,506 4 5,804 - 3,686 - 526 - 10,016 - 77,522 4 605,536 45 474,527 35 85,642 7 - - 138,196 10 (11,907) (1) 1,291,994 96 1,369,516 100
Amount $ 360,329 491 39,358 3,223 1,602 408,302 16,661		Amount 362,971 246 59,999 2,452 - 396,079 8,841	Amount $ 2,349 14,935 31,630 - 5,105 5,787		Amount 2,622 14,995 36,541 2,015 6,778 4,555

			59,806	5	67,506	4
829,966	61	830,588	3,783 2,601 438	- - -	5,804 3,686 526	- - -
- 87,431 257,749 7,649 69,640 95,274 5,238	- 7 19 1 5 7 -	- 97,564 252,134 10,422 68,815 98,278 11,715
			6,822	-	10,016	-
			66,628	5	77,522	4
			605,536 474,527 98,565 11,907 107,983 (12,199)	45 35 7 1 8 (1)	605,536 474,527 85,642 - 138,196 (11,907)	45 35 7 - 10 (1)
522,981	39	538,928
			1,286,319	95	1,291,994	96
$ 1,352,947	100	1,369,516	$ 1,352,947	100	1,369,516	100

(See accompanying notes to financial statements.) Manager: JIH PEI JU

Chairperson: WILBER HUANG

Accounting supervisor: CHANG YA PING

19 -

Abnova (Taiwan) Corporation Statements of Comprehensive Income For the years ended December 31, 2023 and 2022 (Expressed in Thousands of New Taiwan Dollars)

2023	％ 100 (55)	2022
Amount $ 380,593 (208,137)		Amount 410,320 (210,327)	％
			100 (51)
172,456	45	199,993	49
(45,261) (43,437) (38,396) 3,053	(12) (11) (10) 1	(40,349) (41,139) (48,740) (698)	(10) (10) (12) -
(124,041)	(32)	(130,926)	(32)
48,415	13	69,067	17
10,332 152 517 (140) (10,799)	3 - - - (3)	3,463 800 26,053 (132) (4,336)	1 - 6 - (1)
62	-	25,848	6
48,477 4,799	13 1	94,915 20,072	23 5
43,678	12	74,843	18
(618) - -	- - -	304 28,730 -	- 7 -
(618)	-	29,034	7
(292) -	- -	4,216 -	1 -
(292)	-	4,216	1
(910)	-	33,250	8
$ 42,768	12	108,093	26
$	0.72		1.24
$	0.72		1.23

(See accompanying notes to financial statements.) Chairperson: WILBER HUANG Manager: JIH PEI JU - 20 -

Accounting supervisor: CHANG YA PING

Abnova (Taiwan) Corporation Statements of Changes in Equity For the years ended December 31, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars)

Shares	Capital surplus		Retained earnings		Other equity interest	Other equity interest	Total equity
					Exchange differences on translation of foreign financial statements	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income
Ordinary shares		Legal reserve	Special reserve	Unappropriated retained earnings
$ 605,536 - -	474,527 - -	82,766 - -	- - -	39,698 74,843 304	(11,178) - 4,216	20,407 - 28,730	1,211,756 74,843 33,250
-	-	-	-	75,147	4,216	28,730	108,093
- - -	- - -	2,876 - -	- - -	(2,876) (27,855) 54,082	- - -	- - (54,082)	- (27,855) -
605,536 - -	474,527 - -	85,642 - -	- - -	138,196 43,678 (618)	(6,962) - (292)	(4,945) - -	1,291,994 43,678 (910)
-	-	-	-	43,060	(292)	-	42,768
- - -	- - -	12,923 - -	- 11,907 -	(12,923) (11,907) (48,443)	- - -	- - -	- - (48,443)
$ 605,536	474,527	98,565	11,907	107,983	(7,254)	(4,945)	1,286,319

Accounting supervisor: CHANG YA PING

(See accompanying notes to financial statements.) Manager: JIH PEI JU

Chairperson: WILBER HUANG

21 -

Abnova (Taiwan) Corporation Statements of Cash Flows For the years ended December 31, 2023 and 2022 (Expressed in Thousands of New Taiwan Dollars)

Cash flows from operating activities: Profit before tax Adjustments: Adjustments to reconcile profit (loss) Depreciation expenses Amortization expenses Expected credit loss (reversal gains) Interest expense Interest income Share of subsidiaries, associates and joint ventures losses accounted for using equity method Gains on disposals of property, plant and equipment Total adjustments to reconcile profit (loss) Changes in operating assets and liabilities: Changes in operating assets: Notes receivable Accounts receivable Other receivables Inventories Other current assets Total changes in operating assets Changes in operating liabilities: Contract liabilities Accounts payable Other payables Other current liabilities Total changes in operating liabilities Total changes in operating assets and liabilities Total adjustments Cash inflow generated from operations Interest received Interest paid Income taxes paid Net cash flows from operating activities Cash flows used in investing activities: Acquisition of investments accounted for using equity method Disposal of investments accounted for using equity method Cash refund from capital reduction of investees accounted for using equity method Acquisition of property, plant, and equipment Disposal of property, plant, and equipment Acquisition of intangible assets Other financial assets Other non-current assets Other non-current liabilities Net cash flows (outflows) used in investing activities Cash flows from financing activities: Repayment of lease principles Cash dividends paid Net cash flows from financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of the period Cash and cash equivalents at the end of the period	2023 $ 48,477 20,744 10,820 (3,053) 140 (10,332) 10,799 (160)	2022 94,915 21,324 10,739 698 132 (3,463) 4,336 -
	28,958	33,766
	(245) 23,694 (317) (14,548) (7,811)	194 (12,344) (300) 8,583 3,515
	773	(352)
	(273) (60) (4,911) 1,232	(16) 3,515 3,493 (17,884)
	(4,012)	(10,892)
	(3,239)	(11,244)
	25,719	22,522
	74,196 9,878 (140) (7,433)	117,437 3,016 (132) (5,212)
	76,501	115,109
	(1,300) 342 - (19,566) 160 (9,320) 791 5,059 (88)	- - 21,675 (1,390) - (5,240) (350) (7,165) (97)
	(23,922)	7,433
	(6,778) (48,443)	(7,421) (27,855)
	(55,221)	(35,276)
	(2,642) 362,971	87,266 275,705
	$ 360,329	362,971

(See accompanying notes to financial statements.) Chairperson: WILBER HUANG Manager: JIH PEI JU

Accounting supervisor: CHANG YA PING

22 -

Appendix 4 Abnova `（` Taiwan `）` Corporation 2023 Profit Distribution Statement

==> picture [499 x 250] intentionally omitted <==

----- Start of picture text -----

Unit: NTD
Items Amount
Beginning retained earnings 64,923,293
Add: 2023 net profit after tax 43,677,854
Less: Remeasurements of the net defined benefit plan
(618,052)
recognized in retained earnings (Note1)
Net profit after tax of the current period plus the amount of
items other than net profit after tax of the current period
43,059,802
included in the unappropriated retained earnings of the current
year
Less: legal reserve (Note2) (4,305,980)
Less: legal reserve (291,781)
Distributable net profit 103,385,334
Distributable items
Dividend to shareholders- Cash (NTD 0.72/share) (43,598,588)
Unappropriated retained earnings 59,786,746
----- End of picture text -----

Note 1: Other comprehensive profits and losses are recognized according to the pension actuarial report. Note2: It is listed with a net amount of NTD 43,059,802, and its sum of 2023 net profit after tax is NTD 43,677,854, less other comprehensive profits and losses are recognized according to the pension actuarial report NTD 618,052.

Chairperson: Wilber Huang General Manager: Jih Pei Ju Accounting Officer: Chang Ya Ping

23 -

Appendix 5 Abnova `（` Taiwan `）` Corporation Comparison table between the revision and the original of "Rules of Procedure for Board of Directors"

Revision Original Explanation Article 8 (Reference materials, non-voting Article 8 (Reference materials, non-voting According to participants, and holding board meetings) participants, and holding board meetings) the letter (No. When a board meeting is held, the When a board meeting is held, the 1120383996) Chairperson's Office shall furnish the attending Chairperson's Office shall furnish the attending issued by FSC directors with relevant materials for ready directors with relevant materials for ready on January 11, reference. reference. 2024, this As merited by the content of a proposal to be As merited by the content of a proposal to be provision is put forward at the Company’s board meeting, put forward at the Company’s board meeting, updated for personnel from a relevant department or a personnel from a relevant department or a compliance. subsidiary may be notified to attend the subsidiary may be notified to attend the meeting as non-voting participants. meeting as non-voting participants.

When necessary, certified public accountants, When necessary, certified public accountants, attorneys, or other professionals retained by the attorneys, or other professionals retained by the Company may also be invited to attend the Company may also be invited to attend the meeting as non-voting participants and to make meeting as non-voting participants and to make explanatory statements, if they leave the explanatory statements, if they leave the meeting when deliberation or voting takes meeting when deliberation or voting takes place. place.

The chairperson shall call the board meeting to The chairperson shall call the board meeting to order at the appointed meeting time and when order at the appointed meeting time and when more than one-half of all the directors are in more than one-half of all the directors are in attendance. attendance.

If one-half of all the directors are not in If one-half of all the directors are not in attendance at the appointed meeting time, the attendance at the appointed meeting time, the chairperson may announce the postponement of chairperson may announce the postponement of the meeting time on the same date, provided the meeting time, provided that no more than that no more than two such postponements may two such postponements may be made. If the be made. If the quorum is still not met after two quorum is still not met after two postponements, the chairperson shall reconvene postponements, the chairperson shall reconvene the meeting in accordance with the procedures the meeting in accordance with the procedures in Article 3, paragraph 2. in Article 3, paragraph 2.

The number of "all directors," as used in the The number of "all directors," as used in the preceding paragraph and Article 16, paragraph preceding paragraph and Article 16, paragraph 2, subparagraph 2, shall be counted as the 2, subparagraph 2, shall be counted as the number of directors then actually in office. number of directors then actually in office.

Article 11 (Discussion of proposals) Article 11 (Discussion of proposals) According to The board meeting shall follow the agenda The board meeting shall follow the agenda the letter (No. given in the meeting notice. However, the given in the meeting notice. However, the 1120383996) agenda may be changed with the approval of agenda may be changed with the approval of issued by FSC most directors in attendance at the board most directors in attendance at the board on January 11, meeting. meeting. 2024, this

-24-

Revision Original Explanation	Revision Original Explanation	Revision Original Explanation
The chairperson may not declare the meeting closed without the approval of most of the directors in attendance at the meeting. At any time during the course of the board meeting, if the number of directors sitting at the meeting does not constitute a majority of the attending directors, then upon the motion by a director sitting at the meeting, the chairperson shall declare a suspension of the meeting, in which case Article 8, paragraph 5 shall apply mutatis mutandis. If at any time during the proceeding of a board meeting the chairperson is unable to lead the meeting for any reason or declares the meeting closed without approval in accordance with paragraph 2 herein, the chairperson shall elect a proxy, in in which case paragraph 2 of Article 7 herein shall apply mutatis mutandis. The chairperson may not declare the meeting closed without the approval of most of the directors in attendance at the meeting. At any time during the course of the board meeting, if the number of directors sitting at the meeting does not constitute a majority of the attending directors, then upon the motion by a director sitting at the meeting, the chairperson shall declare a suspension of the meeting, in which case Article 8, paragraph 5 shall apply mutatis mutandis. provision is updated for compliance.
Article 18 (Supplementary provisions) These Rules of Procedure were established on February 29, 2008. They were first amended on April 2, 2008, and subsequently amended on December 18, 2008 (2ndamendment), March 29, 2010 (3rdamendment), December 20, 2011 (4thamendment), March 27, 2013 (5thamendment), March 29, 2017 (6thamendment), November 9, 2017 (7thamendment), March 26, 2020 (8thamendment), March 30, 2021 (9thamendment), November 9, 2022 (10thamendment), February 20, 2024 (11thamendment). These Rules of Procedure and future amendments to these Rules shall be adopted by the approval of the meeting of the board of directors and shall be reported to the shareholders meeting. The board of directors maybe authorized to adopt,byresolution.	Article 18 (Supplementary provisions) These Rules of Procedure were established on February 29, 2008. They were first amended on April 2, 2008, and subsequently amended on December 18, 2008 (2ndamendment), March 29, 2010 (3rdamendment), December 20, 2011 (4thamendment), March 27, 2013 (5thamendment), March 29, 2017 (6thamendment), November 9, 2017 (7thamendment), March 26, 2020 (8thamendment), March 30, 2021 (9thamendment), November 9, 2022 (10thamendment). These Rules of Procedure and future amendments to these Rules shall be adopted by the approval of the meeting of the board of directors and shall be reported to the shareholders meeting. The board of directors may be authorized to adopt, by resolution.	Added revision date.

-25-

AI assistant

Abnova — AGM Information 2024

52384_rns_2024-05-24_4bd6fc7b-0220-40de-a991-00d9d8f355c5.pdf

Abnova （ Taiwan ） Corporation Meeting Minutes of General Shareholders’ Meeting 2024

4. Matters for Ratification

No.2

Resolution:

5. Questions and Motions: None

There was no question raised by shareholders at the shareholders' meeting regarding the Reported Matters, Matters for Ratification and Questions and Motions.

6. Adjournment

 The meeting minutes only specify the gist of the meeting, and the contents and procedures of the meeting are subject to the audio and video of the meeting.

Appendix 1

Abnova （ Taiwan ） Corporation 2023 Business Report

I. 2023 Operating Results: (Consolidated Financial Statements)

II. 2024 Business Plan:

1. Business Marketing:

2. Product Development:

(1) miRNA Probe Customization and Catalog Products:

(2) miRNA (circRNA) Sponge

 miRNA Sponge Technology:

(3) Recombinant Antibodies:

(4) Nanobodies:

(5) CellTX[TM] Regeant for Cytotherapy:

(6) mRNA Cancer Vaccine Treatment Platform Development:

III. The effect of external competition, the legal environment, and the overall business environment

1. External Competition:

2. Legal Environment:

3. Overall Business Environment:

Abnova （ Taiwan ） Corporation Inspection Report of Audit Committee

Appendix 3

Independent Auditors’ Report

Opinion

Basis for opinion

Key audit matter

1. Inventory valuation

Other matter

Responsibilities of management and those charged with governance for the financial statements

Auditor’s responsibilities for the audit of the financial statements

KPMG

Abnova Corporation and Subsidiaries

Consolidated Balance Sheets

December 31, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars)

Abnova (Taiwan) Corporation and Subsidiaries Consolidated Statements of Comprehensive Income For the years ended December 31, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars)

Abnova (Taiwan) Corporation and Subsidiaries Consolidated Statements of Changes in Equity For the years ended December 31, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars)

Abnova (Taiwan) Corporation and Subsidiaries Consolidated Statements of Cash Flows For the years ended December 31, 2023 and 2022 (Expressed in Thousands of New Taiwan Dollars)

Independent Auditors’ Report

Opinion

Basis for Opinion

Key audit matter

1. Inventory valuation

Description of key audit matter:

Our principal audit procedures included:

Responsibilities of management and those charged with governance for the financial statements

Auditor’s responsibilities for the audit of the financial statements

KPMG

Abnova (Taiwan) Corporation

Balance Sheets

December 31, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars)

Abnova (Taiwan) Corporation Statements of Comprehensive Income For the years ended December 31, 2023 and 2022 (Expressed in Thousands of New Taiwan Dollars)

Abnova (Taiwan) Corporation Statements of Changes in Equity For the years ended December 31, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars)

Abnova (Taiwan) Corporation Statements of Cash Flows For the years ended December 31, 2023 and 2022 (Expressed in Thousands of New Taiwan Dollars)

Appendix 4

Abnova （ Taiwan ） Corporation 2023 Profit Distribution Statement

Appendix 5

Abnova （ Taiwan ） Corporation Comparison table between the revision and the original of "Rules of Procedure for Board of Directors"

More from Abnova

Abnova AGM Information 2024

Abnova `（` Taiwan `）` Corporation Meeting Minutes of General Shareholders’ Meeting 2024

Abnova `（` Taiwan `）` Corporation 2023 Business Report

Abnova `（` Taiwan `）` Corporation Inspection Report of Audit Committee

Abnova `（` Taiwan `）` Corporation 2023 Profit Distribution Statement

Abnova `（` Taiwan `）` Corporation Comparison table between the revision and the original of "Rules of Procedure for Board of Directors"